NASDAQ · Biotechnology

RANI (RANI) Stock

$0.82 -2.80% NASDAQ: RANI Healthcare

Valuation

MetricValue
Price$0.82
Market Cap$53.58M
P/E Ratio-2.40
P/B Ratio2.14
P/S Ratio20.04
EPS (TTM)$-0.45
52-Week High$3.87
52-Week Low$0.39
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-90.91%
ROA-50.85%
ROCE-90.48%
Gross Margin-1900.00%
Operating Margin-1900.00%
Net Margin-9.29%
Debt/Equity0.14
Current Ratio4.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$0$0$1.0M$2.0M
Operating Profit$-52.0M$-63.0M$-66.0M$-53.0M$-38.0M
Net Profit$-8.0M$-31.0M$-34.0M$-30.0M$-30.0M
EPS$-0.42$-1.28$-1.33$-1.05$-0.45
Op Margin-1899.1%——-5186.2%-2346.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$124.0M$108.0M$58.0M$37.0M$59.0M
Total Liabilities$3.0M$34.0M$32.0M$33.0M$17.0M
Cash$117.0M$27.0M$6.0M$4.0M$19.0M
Borrowings$0$30.0M$30.0M$30.0M$4.0M

Latest News

Daily – Vickers Top Buyers & Sellers for 07/22/2026 Argus Research · Jul 22, 2026 Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 20, 2026 Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing GlobeNewswire · Jul 15, 2026 Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates GlobeNewswire · Jul 9, 2026 Rani Therapeutics Names Nicholas Maestas CFO MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-47.0M$-51.0M$-35.0M$-19.0M
Investing Cash Flow$-1.0M$-74.0M$29.0M$20.0M$-7.0M
Financing Cash Flow$0$-1.0M$0$0$0
Net Cash Flow$44.0M$-90.0M$-21.0M$-2.0M$15.0M
Free Cash Flow$-33.0M$-48.0M$-52.0M$-36.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-26.95%
Quick Ratio3.40
Interest Coverage-12.67
Return 1Y59.11%
Return 3Y-83.86%
Return 5Y—

Ownership

Insiders Held5.01%
Institutions Held43.88%
Institutions Float Held46.20%
Institutional HolderSharesReport Date
RA Capital Management, L.P.8,500,0002026-03-31
Samsara BioCapital, LLC8,500,0002026-03-31
AWM Investment Company, Inc.6,500,0002026-03-31
Vanguard Capital Management LLC4,622,5672026-03-31
SymBiosis Capital Partners, LLC3,667,5852026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
CRBP $9.11 +0.33% -1.95 $168.79M 0.00%
CRDF $0.81 -2.98% -2.58 $53.22M 0.00%
CYBNCybin Inc. $8.28 +1.22% -1.67 $413.02M 0.00%
ELTXElicio Therapeutics, Inc. $3.01 +0.17% -1.27 $57.29M 0.00%

About RANI

RANI is led by CEO Talat Imran, employs 105 people, headquartered in US, publicly traded since 2021.

RANI stock trades at $0.82 with a market capitalization of $53.58M. The stock is valued at a price-to-earnings (P/E) ratio of -2.40, price-to-book of 2.14, price-to-sales of 20.04. Over the past 52 weeks the stock has ranged between $0.39 and $3.87, and currently trades 78.8% below its 52-week high.

On profitability, RANI generates a return on equity (ROE) of -90.91%, return on capital employed of -90.48%, an operating margin of -1900.00%, a net profit margin of -9.29%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides